Lyra Therapeutics, Inc. (LYRA)
OTCMKTS · Delayed Price · Currency is USD
0.7000
-0.0001 (-0.01%)
At close: Jun 8, 2026
Lyra Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 22.06 | 40.58 | 22.35 | 32.55 | 45.75 | 74.59 |
Short-Term Investments | - | - | 80.4 | 65.34 | - | - |
Cash & Short-Term Investments | 22.06 | 40.58 | 102.75 | 97.89 | 45.75 | 74.59 |
Cash Growth | -57.28% | -60.51% | 4.96% | 113.99% | -38.67% | 660.53% |
Other Current Assets | 0.96 | 2.45 | 2.07 | 2.94 | 2.17 | 1.32 |
Total Current Assets | 23.02 | 43.03 | 104.82 | 100.83 | 47.92 | 75.92 |
Net Property, Plant & Equipment | 18.7 | 21.33 | 35.28 | 4.47 | 5.86 | 4.47 |
Other Long-Term Assets | 1.99 | 1.99 | 2.5 | 4.67 | 1.09 | 0.45 |
Total Assets | 43.71 | 66.35 | 142.6 | 109.97 | 54.87 | 80.83 |
Accounts Payable | 0.63 | 1.18 | 3.13 | 2.62 | 3.13 | 0.92 |
Accrued Expenses | 1.1 | 2.59 | 9.37 | 9.03 | 4.26 | 2.98 |
Current Portion of Leases | 4.68 | 4.12 | 5.43 | 1.55 | 1.07 | 0.99 |
Unearned Revenue | 0.01 | 0.4 | 1.66 | 1.28 | 9.79 | - |
Other Current Liabilities | 3.06 | 4.35 | - | - | - | - |
Total Current Liabilities | 9.48 | 12.63 | 19.6 | 14.47 | 18.25 | 4.88 |
Long-Term Leases | 26.7 | 30.26 | 21.45 | 0.67 | 0.38 | 1.45 |
Other Long-Term Liabilities | 11.86 | 11.86 | 12.14 | 14.08 | 1.93 | - |
Total Long-Term Liabilities | 38.56 | 42.12 | 33.58 | 14.74 | 2.31 | 1.45 |
Total Liabilities | 48.04 | 54.75 | 53.18 | 29.21 | 20.55 | 6.34 |
Common Stock | 0 | 0 | 0.06 | 0.03 | 0.01 | 0.01 |
Additional Paid-in Capital | 422.43 | 416.38 | 400.69 | 329.39 | 227.7 | 224.36 |
Accumulated Other Comprehensive Income | - | - | 0.03 | 0.01 | - | - |
Retained Earnings | -426.76 | -404.79 | -311.36 | -248.68 | -193.4 | -149.88 |
Total Common Shareholders' Equity | -4.33 | 11.59 | 89.42 | 80.75 | 34.32 | 74.49 |
Shareholders' Equity | -4.33 | 11.59 | 89.42 | 80.75 | 34.32 | 74.49 |
Total Liabilities & Equity | 43.71 | 66.35 | 142.6 | 109.97 | 54.87 | 80.83 |
Total Debt | 31.38 | 34.38 | 26.88 | 2.22 | 1.45 | 2.44 |
Net Cash (Debt) | -9.32 | 6.2 | 75.87 | 95.68 | 44.29 | 72.15 |
Net Cash Growth | - | -91.83% | -20.70% | 116.01% | -38.61% | 1013.14% |
Net Cash Per Share | -6.50 | 4.76 | 76.17 | 158.22 | 170.54 | 419.98 |
Book Value | -4.33 | 11.59 | 89.42 | 80.75 | 34.32 | 74.49 |
Book Value Per Share | -3.02 | 8.90 | 89.77 | 133.54 | 132.13 | 433.59 |
Tangible Book Value | -4.33 | 11.59 | 89.42 | 80.75 | 34.32 | 74.49 |
Tangible Book Value Per Share | -3.02 | 8.90 | 89.77 | 133.54 | 132.13 | 433.59 |